# Validate low-cost metronomic oral regimens in phase 3 and carry them into guidelines

Source: https://onco.cc/ideas/idea-reg-metronomic-lmic-phase3-to-label/  
OnCo record `idea-reg-metronomic-lmic-phase3-to-label` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Indian trials have shown that tiny daily doses of old oral chemotherapy drugs can help patients with head and neck cancer at a cost of a few dollars a month. These regimens should be proven and adopted worldwide.

## Summary

Tata Memorial Centre's randomised trials of low-dose oral metronomic chemotherapy (methotrexate plus celecoxib, later triple metronomic therapy) in head and neck cancer reported survival comparable or superior to intravenous cisplatin in palliative settings at a fraction of the cost, and low-dose nivolumab added to metronomic therapy improved survival in another trial. These results have had limited uptake outside India. The proposal is a coordinated programme of confirmatory phase 3 trials in several LMICs across common cancers (head and neck, cervical, breast), with an explicit path to WHO essential medicines listing and guideline inclusion.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Metronomic regimens confirmed in multinational phase 3 trials are non-inferior in overall survival to standard intravenous regimens in defined palliative settings at less than a tenth of the drug cost, and are adopted into WHO and national guidelines within two years of publication.
- Rationale: The Indian trials are the most cost-effective oncology results of the past decade and were possible only because a public institution ran them; replication is the step that will make them global practice.
- Proposed test: Fund two multinational phase 3 trials in head and neck and cervical cancer across five LMICs with OS primary endpoints and cost-effectiveness analyses, with WHO involvement from the outset.
- Maturity: early-clinical
- Actor: research

## Sources

- Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014): https://doi.org/10.3332/ecancer.2014.442

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- institutions: [Tata Memorial Centre](https://onco.cc/institutions/tata-memorial/)
- bottlenecks: [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [No incentive to repurpose cheap drugs](https://onco.cc/bottlenecks/b-generic-repurposing/)
- key papers: [The Repurposing Drugs in Oncology (ReDO) Project](https://onco.cc/key-papers/paper-pantziarka-ecancermedicalscience/)
- roadmaps: [Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs](https://onco.cc/roadmaps/chemotherapy-roadmap/), [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-metronomic-lmic-phase3-to-label.json